Saudi J. Med. Pub. Health **Vol. 2,** No. 2, pp 2501-2516 (2025)

Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/202522428

Packaging and Shipping of Infectious Materials: Integrated Health Security Governance, Administrative Compliance, Medical Secretariat Coordination, and Pharmacy Technician Logistics

Fares Nasser Aloteibi [1], Khalefh Gnem Khalefh Aldosari [2], Amani Yahya Ebrahim Hazmi [3], Khulud Awadh Muaysir Alruwaili [4], Musaed Sadullah Alghamdi [5], Majed Saad Yahya Alharbi [6], Abdullah Khalid Salem Alshehri [7], Hind Hlil Alotaibi [8], Wejdan Nasser Saad Aldawsari [8], Hind Mohammed Alqahtani [8], Hind Mohammed Mujaddil Alqahtani [8], Wesam Alsaadi Haidar Haidar [9], Rana Hassan A Hakami [10]

(1) Masawi Health Center,Ministry of Health, Saudi Arabia,
(2) Okaz Health Center Riyadh First Health Cluster,Ministry of Health, Saudi Arabia,
(3) King Fahad Hospital Jazan Phlebotomist,Ministry of Health, Saudi Arabia,
(4) Zaloum Health Center, Ministry of Health, Saudi Arabia,
(5) Diriyah Hospital - Riyadh,Ministry of Health, Saudi Arabia,
(6) Nafi General Hospital,Ministry of Health, Saudi Arabia,
(7) Riyadh Long Term Care Hospital,Ministry of Health, Saudi Arabia,
(8) Al-Muzahmiya Health Center,Ministry of Health, Saudi Arabia,
(9) Jazan Specialized hospital,Ministry of Health, Saudi Arabia,
(10) City/Jazan Specialist Hospital,Ministry of Health, Saudi Arabia

Abstract

Background: The safe transport of infectious substances is a critical biosafety and health security function. Mishandling during packaging or shipping can lead to occupational exposure, environmental contamination, and public health risks.

Aim: This paper aims to outline the regulatory frameworks, classification systems, packaging requirements, and operational practices necessary for the safe transport of infectious materials.

Methods: A comprehensive review of international and U.S. regulatory guidelines, including WHO, UN Model Regulations, DOT Hazardous Materials Regulations, and IATA standards, was conducted. Key operational domains such as classification, packaging, marking, labeling, documentation, and emergency response were analyzed.

Results: Infectious substances are categorized into Category A (high-risk, UN 2814/2900) and Category B (moderate-risk, UN 3373), with exemptions for low-risk specimens. Category A requires UN-certified triple packaging and strict documentation, while Category B mandates robust containment and standardized markings. Training for all stakeholders is essential, with renewal every three years. Emergency preparedness and spill management protocols are integral to risk mitigation.

Conclusion: Safe transport of infectious substances demands a unified system integrating regulatory compliance, standardized packaging, competency-based training, and emergency readiness. Adherence to these measures prevents exposure, ensures diagnostic continuity, and strengthens public health resilience.

Keywords: Infectious substances, Category A, Category B, UN 3373, biosafety, hazardous materials transport, WHO guidelines, IATA, DOT regulations, triple packaging.

Introduction

Infectious substances are broadly defined as materials that contain, or are reasonably expected to contain, pathogens capable of causing disease in humans or animals. Because these materials may be encountered in clinical diagnostics, public health surveillance, biomedical research, and pharmaceutical supply chains, their safe movement across local, national, and international transport networks is not a peripheral operational matter; it is a core biosafety and health security obligation. Failures in packaging integrity, labeling accuracy, or documentation can result in accidental exposure events that endanger laboratory and transport personnel, disrupt continuity of care, and create wider

*Corresponding author e-mail: Fares56931@Gmail.Com (Fares Nasser Aloteibi).
Receive Date: 01 December 2025, Revise Date: 28 December 2025, Accept Date: 31 December 2025

environmental or community risks. Accordingly, the packaging and shipping of infectious substances must be managed as a controlled process governed by standardized containment principles, traceable accountability, and regulatory compliance.[1] The transport of infectious materials is regulated through a multi-layered framework that integrates national hazardous materials laws with international standards intended to harmonize cross-border movement. Handling and shipping responsibilities extend beyond laboratory staff to include couriers, warehouse personnel, receiving units, and administrative coordinators; therefore, training requirements typically mandate that all individuals with roles in classification, packing, documentation, or acceptance of shipments complete appropriate hazardous materials (hazmat) instruction and maintain competency through periodic renewal. In the United States, the Department of Transportation (DOT) enforces hazardous materials rules, while international alignment is supported by the United Nations system and guidance developed in collaboration with the World Health Organization (WHO). A notable regulatory milestone occurred when the Pipeline and Hazardous Materials Safety Administration (PHMSA), operating under the U.S. DOT, revised the Hazardous Materials Regulations (HMR) to incorporate a classification approach shaped by criteria advanced by the WHO, the U.S. Centers for Disease Control and Prevention (CDC), and technical experts in biosafety and transport operations. This approach created clearer risk-based categories that determine the required packaging performance, marking, labeling, and transport conditions. In addition, air transport standards are strongly influenced by the International Air Transport Association (IATA), which operationalizes international requirements through widely adopted dangerous goods rules, including recognition of an "Exempt" designation for certain low-risk specimens.[2]

A central concept in infectious materials transport is that regulatory classification is based on the anticipated severity of harm should an exposure occur, not merely on the source of the specimen. Category A infectious substances are defined by their capacity, upon exposure, to cause permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals. To facilitate standardized identification and emergency response, Category A materials are assigned United Nations (UN) numbers that distinguish human-associated and animal-associated hazards. UN 2814 applies to infectious substances affecting humans, including relevant zoonotic agents and human prions, whereas UN 2900 applies to infectious substances affecting animals.[3] This differentiation supports consistent communication across stakeholders—shippers, carriers, and receivers—while also triggering the highest level of packaging stringency and documentation expectations. By contrast, Category B infectious substances represent a lower level of hazard in which exposure is not generally expected to produce permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals. The risk profile for Category B is therefore considered moderate to low, yet it still requires formal compliance steps because accidental release can remain clinically and operationally consequential. Category B materials are assigned the UN identification number UN 3373, which functions as a universal indicator of regulated biological substance transport and ensures that packaging and handling meet defined protective standards.[4] Not all clinical or biological specimens fall under infectious substance classifications. Exempt human or animal specimens typically include those transported for routine analyses unrelated to infectious disease diagnosis—such as certain cancer biopsy evaluations—or other testing scenarios in which there is a low probability that the sample contains pathogens. These exempt specimens are not treated as dangerous goods, do not receive a UN identification number, and are associated with a comparatively low potential for harm. Nevertheless, their movement still warrants disciplined handling practices, because misclassification or poor containment can undermine confidence in laboratory operations and create avoidable safety incidents.[2] In sum, contemporary transport frameworks emphasize proportionality: the higher the potential consequence of exposure, the more rigorous the packaging and shipping requirements become, thereby protecting workers, patients, and the public through a structured, risk-calibrated system.[1][2][3][4]

Issues of Concern

Transport Regulations

The transport of infectious substances is governed by stringent regulatory frameworks because even a single failure in containment, labeling, or documentation can create disproportionate harm. Unlike many other commodities, infectious materials carry a dual consequence profile: they can injure individuals through direct exposure during handling or accidents, and they can create secondary environmental contamination that is difficult to detect and costly to remediate.[2] For these reasons, regulatory systems are intentionally prescriptive, defining not only what constitutes an infectious substance but also how such material must be classified, packaged, marked, labeled, documented, and accepted for carriage. The United Nations system plays a central harmonizing role through the development of model requirements intended to standardize safe practice across borders and transport modes. In particular, the UN Committee of Experts established the UN Model Regulations on the Transport of Dangerous Goods (UNCETDG), which function as a baseline set of recommendations designed to promote consistent national and international application.[2] This harmonization is not merely bureaucratic; it reduces ambiguity, improves emergency response interoperability, and supports predictable compliance among laboratories, couriers, airlines, and receiving institutions operating in different jurisdictions. Even with model regulations, practical transport governance is not fully uniform, because adoption requires translation into national law and into enforceable carrier policies. The UN Model Regulations commonly require jurisdiction-specific modification to align with domestic legal structures, enforcement capacity, and public health priorities.[2] In parallel, international organizations may issue implementation guidance to operationalize the core standards into procedures that are usable at the bench level and shipping dock level. Moreover, carriers—especially airlines and large courier networks—often apply requirements that exceed minimum legal thresholds. These additional rules may reflect operational risk tolerance, insurance constraints, route-specific security considerations, and the logistical realities of handling diverse cargo streams. As a result, a shipment that meets baseline UN requirements may still be rejected if it fails to satisfy a carrier's added restrictions regarding packagings, overpacks, documentation formatting, or acceptance procedures. Consequently, laboratories and shipping units must treat "compliance" as a multi-layered obligation: alignment with the governing legal standard is necessary but not always sufficient for successful transport [1][2][3].

A further complication is that infectious substances move through multiple transport modalities—air, road, rail, sea, and postal systems—each of which may operate under distinct international modal agreements and operational constraints. International law and modal conventions provide mode-specific rules that translate general hazard principles into practical carriage conditions, including package testing standards, quantity limits, and emergency handling expectations. The World Health Organization has issued consolidated guidance to support consistent interpretation and safe practice across these modes, and laboratory personnel are expected to consult the rules applicable to the specific pathway used for shipment preparation and dispatch. [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] In practice, this means that "one-size-fits-all" internal policies are rarely adequate unless they are deliberately written to meet the most stringent anticipated mode and route requirements [2][3].

Transportation Stakeholders and Training

One of the most consequential operational realities in infectious materials shipping is that responsibility is distributed across many individuals, not limited to the person who physically seals the container. Federal hazardous materials transportation law recognizes this by defining all persons involved in the packaging and shipping process as transportation stakeholders who must receive appropriate training, thereby formalizing a concept of shared accountability across the shipment lifecycle. Individuals who meet these criteria are commonly referred to as hazmat employees or hazmat workers, while a hazmat employer includes any organization or person who engages in activities such as offering hazardous materials for transport, transporting them, manufacturing or certifying packaging, or repairing regulated packagings.[5] This framing is important because it acknowledges that risk is introduced at multiple nodes: classification errors may arise at ordering and accessioning, packaging failures may occur during assembly, documentation errors may occur at administrative interfaces, and acceptance failures may occur at dispatch points. Any one of these breakdowns can create exposure risk or legal noncompliance. Training is therefore not an optional professional development activity; it is a risk-control intervention that directly reduces preventable incidents. The required training domains reflect the complexity of shipping as a safety system rather than a single task. Competency expectations include general awareness and familiarization, function-specific training relevant to the individual's actual duties, safety training (including emergency response actions), security awareness, and—where applicable—security training and driver training for individuals who operate vehicles.[5] [See U.S. Department of Transportation. (2016, October 1). Hazmat Transportation Training Requirements. Pipeline and Hazardous Materials Safety Administration. Retrieved February 10, 2022] Because laboratory workers are routinely at risk of self-exposure in routine handling, and because failures in biocontainment can extend risk beyond the facility into the environment, training must be understood as protecting both occupational health and public health.[6]

Regulatory expectations extend beyond completing a course; they include timeliness, renewal, and documentation. Training should be completed within 90 days of employment in a relevant function and renewed at least every three years to ensure that knowledge remains current and that procedural drift is corrected. Hazmat employees are required to maintain training records that typically include the employee's identity, completion date, training content, trainer qualifications, and a certification statement. Records are retained for defined periods, commonly including several years after the most recent training and a limited interval after the employee leaves the position. Employees who have not completed training may still participate in operations only under the direct supervision of a trained hazmat employee, a safeguard intended to prevent unsupervised decision-making in high-consequence tasks. [See U.S. Department of Transportation. (2016, October 1). Hazmat Transportation Training Requirements. Pipeline and Hazardous Materials Safety Administration. Retrieved February 10, 2022] Importantly, training may be delivered under different regulatory umbrellas—such as Occupational Safety and Health Administration (OSHA) or Environmental Protection Agency (EPA) programs—provided that the required competencies are demonstrably satisfied. This flexibility can be advantageous, but it also increases the administrative burden to ensure that training content truly maps onto hazardous materials shipping duties rather than only general biosafety [3][4][5][6].

Classification System

Correct classification is the keystone of safe transport because it determines every downstream requirement: packaging performance standards, marking and labeling, documentation, quantity limits, and acceptance criteria. Infectious substances may include cultures, patient specimens, biological products, regulated medical waste, and contaminated medical devices or equipment. [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] The classification step must be completed before packaging begins, because packaging selection is not simply a matter of convenience; it must match the hazard category and the applicable transport rules. Category A substances represent the highest level of infectious transport hazard and are defined as materials that, upon exposure, are capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals.[2][3] In practice, classification depends on knowledge of the source material's clinical context, diagnostic suspicion, laboratory findings, or—when necessary—professional judgment. This requirement emphasizes that classification is a clinical-scientific decision as much as it is a logistical one. Cultures of high-consequence pathogens and agents commonly associated with severe disease outcomes are typical examples used in training contexts, and guidance documents provide additional listings to support consistency. [See U.S. Department of Transportation. (2020, April 28). Transporting infectious substances safely. Pipeline and Hazardous Materials Safety Administration. Retrieved January 2, 2022] The correct proper shipping names and UN identification numbers for Category A substances include UN 2814 for infectious substances affecting humans and UN 2900 for infectious substances affecting animals, with additional designations applicable to certain regulated medical waste streams derived from medical treatment activities.[7] [See U.S. Department of Transportation. (2020, April 28) Transporting infectious substances safely. Pipeline and Hazardous Materials Safety Administration. Retrieved January 2, 2022] [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022]

Category B substances are defined by exclusion: they do not meet Category A criteria and are not generally capable of causing permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals.[2] Category B frequently includes diagnostic specimens collected and transported for routine clinical evaluation, where the risk exists but is comparatively lower and more manageable through standardized packaging and handling practices. Category B shipments are typically designated as “Biological substance, Category B” and use the UN number UN 3373 (this is sometimes mistyped in secondary materials, but UN 3373 is the widely recognized identifier for Category B diagnostic specimens).[2][5] Category B–related regulated medical waste streams may have additional designations depending on jurisdiction and waste category.[2] [See U.S. Department of Transportation. (2020, April 28). Transporting infectious substances safely. Pipeline and Hazardous Materials Safety Administration. Retrieved January 2, 2022] [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] Across both categories, a recurring issue of concern is that classification errors propagate risk: under-classification can lead to inadequate containment and insufficient hazard communication, while over-classification can impose unnecessary complexity, increase cost, delay diagnostics, and trigger avoidable transport barriers. Therefore, institutions should treat classification as a controlled decision process supported by clear internal criteria, escalation pathways for ambiguous cases, and documentation practices that allow auditability. When implemented correctly, the combined structure of international model regulations, stakeholder training requirements, and risk-based classification creates a defensible safety system that reduces exposure risk, supports public trust, and enables the essential movement of clinical and laboratory materials through modern healthcare and surveillance networks.[2][5][6]

Exceptions

Despite the existence of a formal classification structure for infectious substances, real-world specimen handling frequently presents uncertainty at the pre-analytical stage. In clinical and research workflows, the shipper may not always have definitive information about the presence, concentration, or pathogenic potential of biological agents at the time packaging decisions must be made. This ambiguity is especially common when specimens are collected for screening, surveillance, or broad diagnostic evaluation rather than for confirmation of a known high-consequence pathogen. Recognizing these operational realities, transport frameworks incorporate defined exceptions for materials that do not meet the regulatory threshold of “infectious substances” under Category A or Category B. In the U.S. regulatory context, Section 173.134(b) of the Hazardous Materials Regulations (HMR) specifies exceptions that exempt certain materials from infectious-substance requirements when they fall outside the definition or do not present the level of hazard contemplated by Category A or Category B controls. [See U.S. Department of Transportation. (2020, April 28). Transporting infectious substances safely. Pipeline and Hazardous Materials Safety Administration. Retrieved January 2, 2022] These exceptions are not a relaxation of safety principles; rather, they represent a risk-based determination that the probability of infection and the consequences of exposure are sufficiently low that the full suite of infectious-substance transport obligations is not warranted, provided that specified handling protocols are followed. A defining feature of exempted substances is that they either contain no biological agents or contain biological agents that are not capable of causing disease in humans or animals. In other words, their hazard profile does not justify the same level of labeling, documentation, and performance-tested packaging required for infectious substances. When correctly applied, exemptions reduce unnecessary regulatory burden, facilitate timely movement of clinical materials, and prevent operational delays that could compromise patient care or research continuity. Nevertheless, exemption status must be approached with disciplined professional judgment, because misclassification in the direction of under-regulation can create avoidable exposure risk to transport workers, laboratory personnel, and the public. The logic of exemptions therefore rests on a careful balance: the regulatory system seeks to reduce friction for low-risk materials without enabling complacency or permitting informal transport practices that erode basic containment standards [5][6][7].

Within the HMR exception framework and parallel international guidance, several classes of materials are commonly cited as examples of exempt substances. These include cultures that are nonpathogenic to humans or animals, which may be used for teaching, quality control, or research in ways that do not entail a credible risk of infection. Exemptions also extend to certain patient specimens collected for screening contexts, such as dried blood spot specimens used in testing paradigms where the sample form and intended analysis yield a low probability of infectious transmission. In addition, biological products—such as blood products intended for transfusion or organs intended for transplantation—are often treated as exempt or differently regulated categories because they are subject to stringent clinical oversight and specialized handling pathways that reduce transport-related hazard in ways distinct from diagnostic infectious shipments. Similarly, medical or clinical waste that has been effectively decontaminated, including by validated autoclaving or incineration, is treated differently because the decontamination step materially alters the risk, converting a potentially infectious material into a noninfectious one under defined conditions. Exemptions may also apply to medical equipment that is free of contaminated liquid, reflecting the practical reality that dry, non-contaminated devices do not present the same exposure risk as liquid-containing devices. Environmental samples such as food, soil, or water—when shipped for research and when they are not reasonably expected to contain agents capable of infecting humans or animals—are likewise frequently referenced as low-risk shipments that may fall under exception categories when appropriate criteria are met. [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] Importantly, exemption does not imply the absence of packaging expectations. Even when a substance is exempt from most infectious-substance requirements, modal rules—particularly for air transport—may still impose containment norms that resemble those used for regulated specimens. The World Health Organization notes that, if transported by air, exemptions are often subject to modal requirements that include a triple packaging system and, for liquids, the inclusion of absorbent material capable of containing the full volume of the specimen in the event of leakage. Beyond these baseline containment practices, exempt materials may be relieved from other infectious-substance regulatory elements, such as UN number assignment and the more extensive marking and labeling set applied to Category A and Category B shipments. [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] This approach reflects a core safety principle: even low-risk biological materials should be packaged in a way that protects handlers from direct contact if a receptacle fails [5][6][7].

In parallel with HMR concepts, the International Air Transport Association (IATA) and the United States Postal Service (USPS) recognize "exempt human or animal specimens" in contexts where samples are transported for routine testing unrelated to diagnosing an infectious disease. These exempt specimens include materials shipped for assays such as drug or alcohol testing, cholesterol measurement, blood glucose evaluation, prostate-specific antigen testing, kidney or liver function testing, pregnancy testing, and diagnostic workups for noninfectious diseases. The emphasis is on low probability of infectious content and the noninfectious intent of testing, which reduces the likelihood that the shipment contains pathogens meeting Category A or B thresholds. While exempt, these specimens still carry practical risks if containment fails, which is why both IATA and USPS specify packaging performance features to ensure that routine specimens remain secure throughout handling. IATA's requirements for exempt specimens commonly include the use of triple packaging, an outer package with at least one surface meeting a minimum dimension of 100 mm × 100 mm, and an outer package capable of withstanding a 4-foot drop test. USPS requirements are substantially similar in insisting on triple packaging, the same minimum surface dimension, and drop-test survivability, while also specifying quantity limits of 500 mL for the primary receptacle and 500 mL for the secondary container. [See Laboratory Continuing Education. (2013). IATA and US Postal Service Exempt Specimens. Lab CE. Retrieved February 10, 2022] These standards are designed to ensure that, even when regulatory classification is "exempt," mechanical stress events during sorting, transport, and delivery do not lead to leakage or breakage that exposes workers or contaminates other mail or cargo [6][7][8].

The concept of exemption intersects with broader shipment requirements because many institutions adopt standardized packaging workflows that apply the triple packaging model across both regulated and exempt specimens to reduce error and maintain consistent practice. In regulated contexts, infectious substances must satisfy packaging, marking, and labeling requirements, and triple packaging is foundational. A widely referenced structure includes three nested components: a primary receptacle, a secondary container, and a rigid outer packaging. [See Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP). (2016, December 1); Packaging and transporting infectious substances. Centers for Disease Control and Prevention. Retrieved January 2, 2022] The primary receptacle contains the specimen itself and must be leakproof. For liquid specimens, absorbent material must be included in a manner that allows absorption of the entire specimen volume should the primary receptacle fail, thereby preventing free liquid from escaping into the secondary or outer layers. This requirement is both a contamination-control measure and a worker-protection measure, limiting the chance that leakage will spread beyond the packaging system. The secondary container must also be leakproof and must fully enclose the primary receptacle. In practice, cushioning and stabilization are often necessary to prevent movement and impact during transport. Where multiple primary receptacles are shipped together, they may be placed within the same secondary container only if they are of the same hazard class, and each receptacle should be wrapped or separated to prevent contact, especially when fragile materials are involved. Documentation—such as requisitions or shipping papers when needed—is typically positioned between the secondary container and the rigid outer packaging so that it remains accessible without opening the sealed secondary containment. The third layer, the rigid outer packaging, is expected to provide structural protection against compression, puncture, and routine mechanical shocks. It must have appropriate dimensions and sufficient strength to protect the internal containers across the anticipated transport pathway. [See World Health Organization. (2021, February 25). Guidance on regulations for the transport of infectious substances 2021-2022. World Health Organization. Retrieved January 2, 2022] [6][7][8].

Beyond containment, preservation of specimen integrity is often necessary, and this introduces additional complexity because temperature-control materials and chemical stabilizers may themselves be regulated as dangerous goods. Coolants and refrigerants are used to maintain required transport temperatures, while stabilizers are used to prevent degradation or to reduce hazards of the specimen matrix. When coolants are required, packaging must maintain integrity at the coolant's operating temperature, and placement is commonly recommended between the secondary and outer package to preserve the sealed nature of the primary and secondary containment while still enabling thermal control. Institutions shipping such materials must ensure that hazmat employers and workers are trained to handle coolants appropriately and that cargo transport units provide adequate ventilation when required. Marking and documentation obligations may expand to address the coolant as a regulated item in addition to the specimen itself. Dry ice and liquid nitrogen are among the most frequently used cold-chain agents. Dry ice is recognized as a dangerous good, with the proper shipping name "dry ice" or "carbon dioxide, solid," and is assigned UN 1845. Liquid nitrogen is also a dangerous good, with the proper shipping name "nitrogen refrigerated liquid," assigned UN 1977. These identifiers matter because they trigger specific hazard communication requirements and influence quantity limits and handling expectations within certain transport modes. The inclusion of regulated refrigerants therefore transforms what might otherwise be a straightforward specimen shipment into a combined-hazard shipment requiring rigorous attention to compatibility, labeling, and compliance with the applicable modal provisions. Stabilizers introduce parallel concerns. Chemicals such as sorbitol, fetal bovine serum, alcohol, and formaldehyde are cited as stabilizers that may be used to prevent degradation or neutralize hazards, but some stabilizers may qualify as dangerous goods depending on concentration and formulation. In regulated packaging practice, stabilizers must be added appropriately to the primary receptacle so that the specimen and stabilizer remain within the leakproof containment system rather than creating external contamination risk. WHO guidance emphasizes careful adherence to manufacturer instructions and transport rules when stabilizers are used, reflecting that chemical preservation is beneficial only when it does not introduce new hazards that exceed the mitigations built into the packaging system [6][7][8].

Taken together, exceptions and exemptions should be understood as part of a coherent risk-based transport architecture rather than as a "loophole" that permits informal shipping. The regulatory logic is that low-probability, low-consequence biological materials can be shipped without the full infectious-substance framework, but only if baseline containment and mode-specific safeguards are maintained. In operational terms, the safest institutional practice is to treat exemption determinations as documented decisions grounded in criteria, to implement standardized triple packaging workflows where feasible, and to ensure that staff competency extends beyond infectious-substance categories to include refrigerants, stabilizers, and the administrative rules imposed by carriers and postal systems. This approach preserves both compliance and safety, while enabling the timely and reliable movement of specimens that modern healthcare, surveillance, and research systems depend upon [5][6][7][8].

Category A Packaging Requirements

Category A infectious substances represent the highest-risk class of regulated infectious materials because exposure can plausibly result in permanent disability or life-threatening or fatal disease in otherwise healthy humans or animals. For that reason, Category A shipments are governed by the most stringent performance-based packaging requirements in the U.S. Hazardous Materials Regulations (HMR). The controlling provisions are located in Section 173.196 of the HMR, and the packaging system must conform to the performance testing standards referenced in CFR §173.609. In practical terms, compliance is not achieved by "good packaging practice" alone; it is demonstrated through the use of packaging components that meet specified engineering and certification benchmarks and that are assembled in a manner consistent with the regulatory design intent. At the center of Category A compliance is the requirement for triple packaging. The system must include a leakproof primary receptacle that directly contains the infectious substance, a leakproof secondary container that encloses and protects the primary receptacle, and a rigid outer packaging that provides structural integrity across the full transport chain. The triple packaging model is not simply a redundancy preference; it is an exposure-control architecture intended to prevent release even when a single layer fails. The outer packaging must display UN certification markings, confirming that the packaging has been tested and certified to meet applicable UN performance standards for dangerous goods transport. This UN certification is not an optional label; it is a core compliance marker indicating the package has met required drop, pressure, and durability thresholds when manufactured and tested under the relevant specifications [8].



Fig. 1: Category A Packaging Diagram.

Temperature conditions add another layer of regulatory specificity. Category A primary or secondary packaging components are indicated for a wide temperature range, generally from −40 °C to 55 °C, because biological shipments may encounter extreme environmental conditions during air cargo loading, ground transport, and storage transitions. When shipments are transported within these temperature extremes, the materials used for primary and secondary receptacles must be compatible and durable—typically glass, metal, or plastic—chosen not only for chemical compatibility but also for mechanical resilience. The closure system must also maintain a leakproof seal under stress and temperature fluctuation. If needed, a heat seal, skirted stopper, or metal crimp seal should be used to ensure integrity. When screw caps are used, they must be secured to prevent loosening during vibration or pressure changes, and this may require paraffin sealing tape or a manufacturer-designed locking closure. The rigid outer packaging must also meet minimum dimensional requirements, including at least one surface with a minimum dimension of 100 mm × 100 mm (3.9 in × 3.9 in), ensuring sufficient space for mandatory hazard communication marks and labels and facilitating stable handling in cargo systems. The regulatory basis and interpretive guidance for these requirements are summarized in the DOT's infectious-substance transport resources. [See U.S. Department of Transportation. (2020, April 28). Transporting infectious substances safely. Pipeline and Hazardous Materials Safety Administration. Retrieved January 2, 2022]

Category B Packaging Requirements

Category B infectious substances generally present a lower consequence profile than Category A substances, but they remain regulated dangerous goods because they can still cause infection if containment fails. Although Category B shipments are often operationally simpler than Category A shipments, they are not "unregulated." They must comply with the packaging standards described in CFR §173.199, and shippers must assemble packages capable of tolerating routine mechanical and pressure stressors that occur during transport. The Category B framework is intentionally structured to achieve reliable containment while reducing the more intensive certification and documentation obligations that apply to Category A materials. A critical Category B requirement is the use of appropriate markings on the outer packaging, including the proper shipping name "Biological substance, Category B" placed adjacent to the marking, and the required UN 3373 package marking. The UN 3373 mark functions as a standardized visual indicator to carriers and handlers that the package contains a regulated biological substance and should be handled according to applicable safety procedures. Unlike Category A, Category B does not require the same UN specification outer packaging certification mark for infectious substances, but the overall packaging must still satisfy performance criteria, including durability and containment. From an engineering standpoint, Category B packaging must withstand pressure differentials that can occur in air transport, including an internal pressure that produces a pressure difference of 95 kPa or higher. This requirement is highly operational: without adequate pressure tolerance, sealed containers can leak or rupture in response to reduced cabin pressure or temperature-related expansion. For surface transport modes such as road, rail, or sea, the packaging system may incorporate a rigid secondary container or a rigid outer container, but at least one of these layers should be rigid. If the secondary packaging is soft, the outer packaging must be rigid, and conversely, if the outer packaging is soft, the secondary must be rigid. Air transport is stricter: the outer packaging must always be rigid, reflecting the higher mechanical and pressure variability associated with air cargo handling. In addition, the full packaging must pass a 1.2-meter drop test to demonstrate that it can survive routine drops, impacts, and conveyor transitions without compromising containment. It is also important to note that some forms of medical or clinical waste categorized as Category B under specific waste codes may not be required to follow triple packaging in the same way that diagnostic specimens do, reflecting the distinct regulatory logic applied to waste streams versus clinical diagnostic shipments [7][8].



Fig. 2: Category B Packaging Diagram.

Marking and Labeling

Once the appropriate packaging system has been correctly assembled, marking and labeling become the next essential compliance layer. Marking and labeling are not administrative formalities; they are hazard communication tools designed to prevent mishandling, guide emergency response, and ensure that transport workers and receiving facilities can immediately identify the nature of the hazard. Laboratory personnel must therefore apply marks and labels that clearly identify the package, describe the regulated contents, and indicate compliance with packaging performance requirements, consistent with WHO guidance on dangerous goods transport. At a minimum, the package should bear the sender's name and address, the consignor (shipper) information where applicable, and the consignee (receiver) name and address, ensuring traceability and enabling rapid contact if a transport incident occurs. The UN number and proper shipping name must be included for regulated infectious substances, distinguishing between Category A and Category B frameworks. If the shipment uses a coolant, the coolant's UN number and proper shipping name must also appear, followed by the phrase "AS COOLANT," and the net quantity of the coolant must be specified. This requirement matters because coolants such as dry ice and liquid nitrogen are themselves regulated dangerous goods and present hazards distinct from the infectious substance. In Category A shipments, additional marking obligations apply, including the UN packaging symbol and certification markings, as well as the name and contact information of the responsible person for the shipment. For Category B shipments, the outer package must display the UN 3373 mark with the correct dimensions and must show the proper shipping name "Biological substance, Category B" in a visible location. In addition to marks, packages may require hazard labels, handling labels, or both. Hazard labels typically take a diamond shape with minimum dimensions of 100 mm × 100 mm and indicate the hazard class associated with dangerous goods; a single package may require multiple hazard labels if multiple regulated hazards are present (for example, infectious substance plus dry ice). Handling labels communicate how the shipment must be oriented or restricted during transport and may include orientation arrows for liquids, Cargo Aircraft Only (CAO) labels, and warning labels for cryogenic liquids. The combined purpose is to reduce preventable incidents by making safe handling expectations visible at every transfer point in the transport chain [6][7][8].

Documenting Shipments

Documentation requirements function as the legal and operational record of what is being shipped, how it has been classified, and what emergency information should accompany it. For Category A substances, the UN Model Regulations require a Dangerous Goods Transport Document (DGTD). This document is a formal declaration that must include shipper and receiver information, the date of signature, a description of the dangerous goods, the net quantity of dangerous goods, any special handling requirements, emergency response information, and the shipper's certification or declaration statement. The DGTD is critical because it establishes a standardized, auditable record that carriers can use to confirm compliance and that responders can use to guide incident actions. Category B shipments, in contrast, do not require a DGTD under the same framework, reflecting the lower hazard tier and a regulatory preference to reduce administrative barriers while preserving packaging and marking standards. However, operational practice still often includes internal tracking documentation, laboratory chain-of-custody paperwork, and receiving logs to maintain accountability and specimen integrity. International air transport adds additional documentation requirements. Hazardous goods transported by air typically require an air waybill in addition to the DGTD for Category A. The air waybill is a general air cargo requirement for all goods transported by air, but when dangerous goods are involved, particular sections become especially important. The "Handling Information" box and the "Nature and Quantity of Goods" box must be completed to ensure the carrier has a clear understanding of the shipment's hazards and handling limitations. The documentation framework thus becomes a functional extension of hazard communication, ensuring that the information available on the package exterior is also mirrored in transport records that follow the shipment through the logistics pathway. [See World Health Organization. (2021, February 25) [6][7][8].



Fig. 3: Packaging flow chart.

Emergency Response Information

Emergency preparedness is an indispensable component of infectious-substance transport because even low-frequency incidents can produce high-consequence outcomes. All employees in the hazardous materials transport chain must know initial emergency response procedures and understand whom to notify if an incident occurs. [8] Emergency readiness is not confined to the carrier; the shipper and consignee must also be capable of providing specific shipment information if an incident prompts inquiry from responders or regulators. For Category A shipments, two related but distinct contact requirements are emphasized. The first is the name and telephone number of the person responsible for the shipment, and this information should be marked on the outside of the package. The person responsible may be the shipper, the receiver, or a qualified third party, but regardless of identity, this person must be positioned to provide authoritative information about the shipment. The second requirement is a 24-hour emergency response telephone number that is staffed by someone knowledgeable about emergency response requirements and incident mitigation information specific to the shipped material. This 24-hour number is not typically printed on the exterior of the package; instead, it is included in the additional handling information section of the shipper's declaration. [9] This distinction matters operationally: the package exterior enables rapid identification and responsible-person contact, while the formal declaration provides the round-the-clock emergency line for deeper response coordination [7][8][9].

In an incident involving a Category A shipment, responders should use the 24-hour emergency contact number listed on the shipper's declaration for expert guidance. However, both the person responsible and the emergency contact function must be sufficiently informed about the shipment's contents to provide meaningful risk assessment information, including expected routes of exposure and immediate exposure-response measures. [8] Examples of initial response recommendations often include promptly washing exposed skin with soap and water for at least 15 minutes, using an eyewash station if ocular exposure is suspected, notifying supervisors and institutional safety leadership, seeking medical evaluation without delay, isolating the area to prevent secondary exposures (for example, using caution tape or physical barriers), and maintaining clear communication to keep uninvolved personnel out of the affected area until qualified responders arrive. [10] The objective of overarching is to stabilize the situation quickly, prevent further exposures, and initiate institutionally coordinated mitigation [7][8][9][10].

Infectious Substance Spill Management

When spills occur, response speed and procedural discipline are decisive for preventing escalation from a localized accident to a broader exposure event. Prompt, structured action helps reduce aerosol exposure, limits surface contamination, and preserves the safety of staff and the surrounding environment. In the event of an infectious substance spill, initial guidance prioritizes immediate self-protection and area control. Individuals should avoid inhaling potentially airborne material by promptly leaving the room, removing gloves, and notifying others to evacuate. Closing the door behind them is essential for containment, and a visible warning sign should be posted to prevent accidental entry. Contaminated clothing should be removed carefully, with exposed surfaces folded inward to limit spread, and disposed of in an appropriate biohazard bag. Exposed skin should be thoroughly washed with soap and water, after which the incident should be reported to a supervisor and the institutional safety office so that the response remains coordinated and documented. [11] [12] These steps are designed to be executed rapidly and consistently, recognizing that early actions frequently determine whether secondary exposures occur. The cleaning procedure is equally structured and should align with established laboratory biosafety protocols. Immediately after a spill, aerosols should be allowed time to dissipate before reentry, commonly for a minimum of 30 minutes, to reduce inhalation risk. Upon reentry, the response team should assemble appropriate supplies such as disinfectant, paper towels, biohazard bags, and forceps. Personal protective equipment must be selected to match spill severity and anticipated exposure risk, commonly including a lab coat, face protection, utility gloves, and booties, with a HEPA-filtered respirator considered in situations where aerosol risk is higher or where the agent's hazard profile warrants enhanced respiratory protection. [13] [14]

Containment and decontamination should then proceed methodically. The spill area should be covered with disinfectant-soaked towels, and disinfectant should be poured around—not forcefully onto—the spill to avoid splashing and expanding the contaminated zone. A contact time of at least 20 minutes is recommended to ensure disinfectant efficacy against potential pathogens. Sharps must never be handled with bare hands; forceps should be used and sharps disposed of in an approved sharps container. Surrounding areas should be wiped down to address the possibility of micro-splashes. After adequate contact time, materials used for absorbance and wiping should be placed into a biohazard bag. The area may then be re-treated with an appropriate disinfectant such as a 10% household bleach solution, with an additional contact period of approximately 15 minutes before allowing the surface to air-dry or be wiped down again. Contaminated disposable materials and PPE should be placed into a biohazard bag for autoclaving or other approved disposal processing. Finally, thorough hand hygiene and washing of any potentially exposed skin are essential to close the loop on personal safety. [10] This layered approach is designed to minimize risk, support consistent practice, and maintain a defensible institutional safety culture.

List of Category A Infectious Substances

A Category A list is used operationally to support classification decisions and to reduce the risk of mislabeling high-consequence materials. The following Category A substances affecting humans (UN 2814) are presented as adapted from DOT resources. Bacillus anthracis cultures; Brucella abortus cultures; Brucella melitensis cultures; Brucella suis cultures; Burkholderia mallei (Pseudomonas mallei) cultures only; Burkholderia pseudomallei (Pseudomonas pseudomallei) cultures; Chlamydia psittaci (avian strains) cultures; Clostridium botulinum cultures; Coccidioides immitis cultures; Coxiella burnetii cultures; Crimean-Congo hemorrhagic fever virus; Dengue virus cultures; Eastern equine encephalitis virus cultures; Escherichia coli verotoxigenic cultures; Ebola virus; Flexal virus; Francisella tularensis cultures; Guanarito virus; Hantaan virus; hantaviruses causing hemorrhagic fever with renal syndrome; Hendra virus; Herpes B virus cultures; Human immunodeficiency virus cultures; Highly pathogenic avian influenza virus cultures; Japanese encephalitis virus cultures; Junin virus; Kyasanur forest disease virus; Lassa virus; Machupo virus; Marburg virus; Monkeypox virus; Mycobacterium tuberculosis cultures only; Nipah virus; Omsk hemorrhagic fever virus; Poliovirus cultures; Rabies and other lyssaviruses cultures; Rickettsia prowazekii cultures; Rickettsia rickettsii cultures; Rift Valley fever virus cultures; Russian spring-summer encephalitis virus cultures; Sabia virus; Shigella dysenteriae type I cultures; Tick-borne encephalitis virus cultures; Variola virus; Venezuelan equine encephalitis virus cultures; Vesicular stomatitis virus cultures; West Nile virus cultures; Yellow fever virus cultures; Yersinia pestis cultures. Category A substances affecting animals (UN 2900) likewise include agents with severe disease potential in animals and major agricultural or ecological consequences. Examples include African swine fever virus cultures; Avian paramyxovirus type 1 (velogenic Newcastle disease virus) cultures; Classical swine fever virus cultures; Foot-and-mouth disease virus cultures; Lumpy skin disease virus cultures; Mycoplasma mycoides (contagious bovine pleuropneumonia) cultures; Peste des petits ruminants virus cultures; Rinderpest virus cultures; Sheep-pox virus cultures; Goatpox virus cultures; and Swine vesicular disease virus cultures [9][10][11].

Integrating Requirements into Operational Practice

In high-reliability environments such as laboratories, hospitals, and shipping departments, these requirements are best understood as a unified system rather than isolated rules. Category A packaging focuses on UN-certified performance and maximal containment redundancy, while Category B emphasizes robust containment and standardized UN 3373 identification. Marking and labeling ensure that hazard communication is preserved across every handoff, documentation ensures traceability and legal compliance, and emergency response planning ensures that incidents can be contained quickly and competently. When institutions treat these requirements as an integrated workflow—supported by training, checklists, and quality oversight—they reduce both the probability of transport incidents and the consequences if failures occur, thereby protecting personnel, the public, and the continuity of healthcare and public health operations [10].

Clinical Significance

The safe packaging and shipment of infectious substances is a core biosafety and health security function because transport-related failures can produce consequences that extend well beyond the immediate laboratory environment. When infectious materials are mishandled—whether through inadequate containment, incorrect classification, improper labeling, or insufficient worker training—exposure risk emerges at multiple points along the transport chain, including during specimen collection, handoff to couriers, cargo handling, and receipt at destination facilities. The clinical significance of these practices lies in their capacity to prevent avoidable infections among laboratory personnel, healthcare workers, transport staff, and the broader community, while also preserving the integrity of clinical diagnostics and public health surveillance. Because laboratories differ widely in infrastructure and expertise, and because infectious agents vary in virulence and routes of transmission, adherence to standardized packaging and shipping requirements becomes a critical control measure that links laboratory medicine to outbreak prevention and emergency preparedness. In practice, laboratories around the world—research facilities, diagnostic laboratories, hospital laboratories, and national reference laboratories—must be prepared to manage a wide spectrum of materials ranging from routine clinical specimens to high-consequence Category A pathogens. This readiness is not merely a regulatory expectation; it is a direct patient-safety and community-protection mandate. Inadequate preparedness has historically led to unintentional exposures, demonstrating that even well-intentioned institutions can become sources of harm when biosafety systems are incomplete, inconsistently applied, or poorly maintained. The literature has documented that laboratory environments have not always been sufficiently equipped to handle infectious substances in a manner that reliably prevents exposure, and that gaps in training and procedural standardization can translate into real-world adverse outcomes.[6][15] From a clinical perspective, every preventable exposure incident carries downstream implications: post-exposure evaluation, potential prophylaxis, staff absence, workflow disruption, psychological distress among personnel, and—in worst cases—secondary transmission that transforms a laboratory lapse into a public health event [6][11][12][13][14][15].

Fig. 4: Example of Packaging Labels.

The example of Salmonella mishandling illustrates how localized procedural failures can propagate into community-level consequences. In 2013, community outbreaks were traced back to certain teaching laboratories across the United States, where improper containment and mishandling of Salmonella samples contributed to infection events beyond the laboratory setting.[6] Investigation of these episodes identified a lack of consistent biosafety practices and the absence or weakness of emergency response procedures within the involved laboratories.[6] Clinically, this is highly consequential because Salmonella outbreaks can cause substantial morbidity, particularly among vulnerable populations, and because such outbreaks undermine trust in educational and research institutions that are expected to model best practices. Operationally, these incidents highlight a central principle: biosafety is not only about the availability of equipment, but also about institutional culture, standard operating procedures, competency-based training, supervision, and routine auditing. Without consistent implementation, even well-designed guidelines fail to translate into safe practice. Therefore, it becomes paramount that all laboratories handling dangerous substances develop and maintain protocols aligned with appropriate national and international requirements, ensuring that containment is reliable and that environmental exposure is prevented.[6]

The urgency of robust packaging and shipping practices has grown in recent years as emerging and re-emerging pathogens have repeatedly tested global preparedness. High-profile public health crises—such as Ebola, Zika, and COVID-19—have demonstrated that the movement of clinical specimens is not an occasional event confined to specialized centers, but a routine and essential component of diagnostic confirmation, research, and coordinated response. During such events, contaminated specimens are frequently transported to specialized reference laboratories for confirmatory diagnosis and advanced testing; they may also be shipped internationally to support collaborative research, assay development, and genomic surveillance. These realities elevate the clinical significance of correct packaging and shipping because the volume, urgency, and geographic scope of specimen movement increases precisely when systems are under the greatest strain. Under outbreak conditions, the margin for error narrows: personnel may be newly assigned, supply chains may be stressed, and the consequences of a single breach can be amplified by heightened transmissibility, limited treatment options, or public fear. Evidence from the period following the 2014–2016 Ebola epidemic underscored that many medical laboratories in the United States were not adequately prepared to handle Ebola specimens and other Category A infectious substances.[16] This lack of preparedness was not limited to physical resources; it also involved deficits in protocols, practical skills, and workforce training, including insufficient readiness to manage infectious waste generated during testing and transport.[16] The clinical implications are substantial. Category A pathogens, by definition, can cause life-threatening disease following exposure, which means that the tolerable risk threshold for containment failure is extremely low. If laboratories lack the capability to package, transport, and dispose of high-risk materials correctly, they not only endanger workers but also jeopardize the reliability of the broader public health response, which depends on safe and timely movement of specimens to the facilities capable of definitive testing [16].

Importantly, outbreaks and transport-related incidents have also served as catalysts for systemic improvement. When gaps in knowledge and training are exposed—through laboratory-associated infections, shipping incidents, or deficiencies identified during emergency response—institutions often respond by strengthening biosafety policies, standardizing procedures, upgrading packaging practices, and expanding competency-based training programs.[6][16] While reactive improvement is preferable to persistent vulnerability, the clinical goal is proactive readiness, especially given that emerging threats can appear with little warning. Each high-profile epidemic has revealed a consistent lesson: safe specimen transport is not a peripheral administrative task, but a frontline infection-prevention intervention that protects staff, preserves laboratory capacity, and prevents secondary spread. The COVID-19 pandemic further reinforced the significance of comprehensive biosafety systems, including waste handling and transport procedures. Hospitals and laboratories were compelled to develop and refine protocols for managing and disposing of COVID-19–related waste and potentially contaminated materials, recognizing that failures in waste handling or transport could create avoidable risks for staff and the environment.[17][18] In clinical settings, where diagnostic throughput and infection-control demands were simultaneously high, clear procedures helped standardize practice across teams and shifts, reducing variability that can lead to errors. Moreover, the pandemic illustrated how biosafety practices intersect with continuity of care: if laboratory personnel are exposed and quarantined, or if a facility must pause operations due to safety concerns, diagnostic delays can impair patient management and weaken surveillance. In sum, the clinical significance of packaging and shipping infectious substances is anchored in prevention: preventing exposure, preventing secondary transmission, preventing disruption of essential diagnostic functions, and preventing erosion of public trust. The documented history of laboratory-associated outbreaks and preparedness gaps shows that risk is not theoretical; it is operational and recurrent.[6][15][16] Consequently, laboratories must treat packaging and shipping as a high-reliability process supported by clear protocols, regular training and retraining, and an institutional safety culture that anticipates emerging threats rather than responding after harm occurs. The evolution of biosafety guidelines and hospital protocols during recent epidemics demonstrates that improvement is achievable, but also that sustained vigilance is required to ensure that the movement of infectious materials—an indispensable feature of modern medicine and public health—does not become an avoidable source of harm.[17][18]

Nursing, Allied Health, and Interprofessional Team Interventions

Competence in handling infectious substances is an essential patient-safety and occupational-safety expectation across the healthcare workforce, not only within laboratory departments. Nurses, medical assistants, phlebotomists, radiology and endoscopy staff, respiratory therapists, and other allied health professionals routinely interact with specimens and clinical waste during everyday care. Even when they are not the individuals formally designated to package and ship infectious materials, they frequently perform the upstream tasks that determine whether materials enter the laboratory pathway safely. For example, nurses and allied health professionals may be responsible for collecting, labeling, and transporting patient specimens to the laboratory, placing specimens into appropriate biohazard bags, and ensuring that requisition forms are handled in a manner that reduces contamination risk. In addition, they often participate in the downstream workflow by disposing of sharps, contaminated dressings, and procedure-related materials, which can include items that carry viable pathogens. Within ambulatory clinics and inpatient units, nursing staff commonly manages medical waste generated from vaccinations, medication administration, venipuncture, wound care, and minor procedures such as biopsies or point-of-care testing. Interventions at this stage center on consistent application of standard precautions, correct segregation of waste streams, and adherence to facility protocols for biohazard disposal. Practical measures include using puncture-resistant sharps containers, avoiding recapping needles, promptly containing any leakage, and recognizing when a specimen requires enhanced precautions due to suspected high-risk infection. When staff identify uncertainty—such as unclear patient isolation status, a leaking container, or unexpected specimen characteristics—an important intervention is timely escalation to infection control, the laboratory, or environmental services before the material is moved further along the chain. It is neither realistic nor necessary for all healthcare professionals to hold the same depth of knowledge as certified laboratory personnel or environmental service workers who are directly responsible for regulated packaging and shipping processes. Nevertheless, foundational literacy in biosafety principles meaningfully reduces unintentional exposure risk. Core competencies for non-laboratory staff include understanding biohazard signage, using appropriate personal protective equipment, maintaining hand hygiene, recognizing exposure incidents, and following immediate response procedures such as isolating spills, reporting promptly, and seeking occupational health guidance. From an interprofessional standpoint, effective interventions also rely on clear handoff communication, accessible standard operating procedures, and periodic refresher training that aligns clinical workflows with biosafety regulations, thereby protecting staff, patients, and the community [16][17][18].

Conclusion:

The packaging and shipping of infectious substances represent a high-stakes process that directly impacts occupational safety, public health, and diagnostic reliability. Regulatory frameworks such as WHO guidance, UN Model Regulations, and DOT Hazardous Materials Regulations provide a structured approach to classification, containment, and hazard communication. Category A substances, due to their severe pathogenic potential, require UN-certified triple packaging and rigorous documentation, while Category B substances demand standardized containment and clear marking under UN 3373. Exempt specimens, though lower risk, still necessitate disciplined handling to prevent accidental exposure. Training emerges as a cornerstone of safety, ensuring that all stakeholders—from laboratory staff to couriers—understand classification, packaging, and emergency protocols. Competency-based education, coupled with periodic renewal, reduces procedural drift and strengthens institutional safety culture. Emergency preparedness, including spill management and 24-hour response systems, further mitigates risk during transport incidents. Ultimately, safe transport is not an isolated technical task but an integrated workflow combining regulatory compliance, operational discipline, and interprofessional collaboration. In an era of emerging pathogens and global health crises, proactive adherence to these standards is essential to prevent harm, maintain diagnostic continuity, and uphold public trust in healthcare systems.

References:

1. Capoor MR, Bhowmik KT. Current perspectives on biomedical waste management: Rules, conventions and treatment technologies. Indian journal of medical microbiology. 2017 Apr-Jun:35(2):157-164. doi: 10.4103/ijmm.IJMM_17_138.
2. Pearson JE. Regulatory constraints for the transport of samples and compliance with the World Organisation for Animal Health (OIE) standards for biosecurity and biocontainment. Developments in biologicals. 2007:128():59-68
3. Pearson JE, Edwards S. Transportation of reagents, reference materials and samples: the international perspective. Developments in biologicals. 2006:126():61-70; discussion 324-5
4. Blanchard PC. Constraints on transportation of reagents, reference materials and samples, difficulties and possible solutions: a user's perspective. Developments in biologicals. 2006:126():71-6; discussion 324-5
5. Richmond JY, Nesby-O'Dell SL. Laboratory security and emergency response guidance for laboratories working with select agents. Centers for Disease Control and Prevention. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2002 Dec 6:51(RR-19):1-6
6. Emmert EA, ASM Task Committee on Laboratory Biosafety. Biosafety guidelines for handling microorganisms in the teaching laboratory: development and rationale. Journal of microbiology & biology education. 2013:14(1):78-83. doi: 10.1128/jmbe.v14i1.531.
7. Windfeld ES, Brooks MS. Medical waste management - A review. Journal of environmental management. 2015 Nov 1:163():98-108. doi: 10.1016/j.jenvman.2015.08.013.
8. Van Raemdonck K, Macharis C, Mairesse O. Risk analysis system for the transport of hazardous materials. Journal of safety research. 2013 Jun:45():55-63. doi: 10.1016/j.jsr.2013.01.002.
9. Ren C, Chen B, Xie F. Identifying Key Factors of Hazardous Materials Transportation Accidents Based on Higher-Order and Multilayer Networks. Entropy (Basel, Switzerland). 2023 Jul 10:25(7):. doi: 10.3390/e25071036.
10. Vijayan V, Sern BNB, Johnson B. Modified Efficient and Simple Method for Biological Spill Cleanup. Applied biosafety : journal of the American Biological Safety Association. 2019 Sep 1:24(3):141-146. doi: 10.1177/1535676019850689.

11. Aldhamy H, Maniatopoulos G, McCune VL, Mansi I, Althaqafy M, Pearce MS. Knowledge, attitude and practice of infection prevention and control precautions among laboratory staff: a mixed-methods systematic review. Antimicrobial resistance and infection control. 2023 Jun 13:12(1):57. doi: 10.1186/s13756-023-01257-5.
12. Ionescu G, Neguţ M, Combiescu AA. [Biosafety and biosecurity in the medical laboratory. Update and trends]. Bacteriologia, virusologia, parazitologia, epidemiologia (Bucharest, Romania : 1990). 2007 Jul-Dec:52(3-4):91-9
13. Jaramillo S, King KC. Toxic Exposure Hazardous Materials. StatPearls. 2024 Jan
14. Kening MZ, Groen K. Personal Protective Equipment. StatPearls. 2025 Jan
15. Peng H, Bilal M, Iqbal HMN. Improved Biosafety and Biosecurity Measures and/or Strategies to Tackle Laboratory-Acquired Infections and Related Risks. International journal of environmental research and public health. 2018 Nov 29:15(12):. doi: 10.3390/ijerph15122697.
16. Le AB, Hoboy S, Germain A, Miller H, Thompson R, Herstein JJ, Jelden KC, Beam EL, Gibbs SG, Lowe JJ. A pilot survey of the U.S. medical waste industry to determine training needs for safely handling highly infectious waste. American journal of infection control. 2018 Feb:46(2):133-138. doi: 10.1016/j.ajic.2017.08.017.
17. Capoor MR, Parida A. Current perspectives of biomedical waste management in context of COVID-19". Indian journal of medical microbiology. 2021 Apr:39(2):171-178. doi: 10.1016/j.ijmmb.2021.03.003.
18. Ilyas S, Srivastava RR, Kim H. Disinfection technology and strategies for COVID-19 hospital and bio-medical waste management. The Science of the total environment. 2020 Dec 20:749():141652. doi: 10.1016/j.scitotenv.2020.141652.